Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.
about
How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future DirectionsTipping the balance both ways: drug resistance and virulence in Candida glabrataCandida colonization index and subsequent infection in critically ill surgical patients: 20 years laterEpidemiology and risk factors for invasive candidiasisCan host receptors for fungi be targeted for treatment of fungal infections?Characterization of Virulence-Related Phenotypes in Candida Species of the CUG Clade.Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated CandidiasisSingle or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!Fitness trade-offs restrict the evolution of resistance to amphotericin BCoriandrum sativum L. (Coriander) essential oil: antifungal activity and mode of action on Candida spp., and molecular targets affected in human whole-genome expressionSystematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genesInvasive candidiasis: from mycobiome to infection, therapy, and prevention.Resistant pathogens, fungi, and viruses.Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.Bloodstream infections by Malassezia and Candida species in critical care patients.Sphingolipid biosynthetic pathway genes FEN1 and SUR4 modulate amphotericin B resistance.Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in ShanghaiMolecular epidemiology and azole resistance mechanism study of Candida guilliermondii from a Chinese surveillance system.Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients.Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)Comparison of the accuracy of two conventional phenotypic methods and two MALDI-TOF MS systems with that of DNA sequencing analysis for correctly identifying clinically encountered yeasts.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Host cell invasion by medically important fungiEpidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013Development and validation of an in-house database for matrix-assisted laser desorption ionization-time of flight mass spectrometry-based yeast identification using a fast protein extraction procedure.The Effect of Essential Oils and Bioactive Fractions on Streptococcus mutans and Candida albicans Biofilms: A Confocal Analysis.The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected].Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).Nontoxic antimicrobials that evade drug resistance.Fibronectin-, vitronectin- and laminin-binding proteins at the cell walls of Candida parapsilosis and Candida tropicalis pathogenic yeasts.Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database.Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro studyInhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth.Photodynamic therapy of oral Candida infection in a mouse model.Antifungal Activity of 14-Helical β-Peptides against Planktonic Cells and Biofilms of Candida SpeciesRapid development of Candida krusei echinocandin resistance during caspofungin therapy.Candida krusei form mycelia along agar surfaces towards each other and other Candida species.
P2860
Q26771113-1A18B10F-7095-49B7-B855-4EBBE9019426Q26996199-3C9691ED-2A7E-43E1-9631-1C6D51ECC1A6Q27012454-676CD509-8688-42DE-A497-7CCE457B48AAQ27024911-EDCD77EE-971B-4183-99E3-FD8B8F7996EEQ27026653-268BEEBD-78F4-4F87-80A0-920FCED9BEEDQ27322862-2F3D8741-B6F5-45DB-AD5A-58D07BEBF41CQ27347943-0CD1D569-D65C-4046-BE5C-B227FBE440C2Q28082570-C81144C2-DE5C-431F-BA4A-E997B5CDA8C3Q28534687-1740EF95-4937-4D8E-8B52-A2339FD7BF22Q28539436-C07B1444-660E-4BB0-ADA8-72AEA0C4A600Q28539874-30F2FA05-F840-489D-8331-AD654317BC0CQ30251428-7C79FE03-D9C8-4B3A-A7E6-C0AD4BAE382CQ30301237-78E6DD9E-2CA5-4520-86EE-5C386F9A53F6Q30826889-4C897BB8-4FDE-4080-8050-9883DFF32A73Q30834974-43034CF5-0186-45CF-86BB-A93521430550Q31151975-1A4393CD-2786-4C57-A5C2-262085403DB7Q33622748-09D95220-F664-45A6-9BDB-D658F2A850BEQ33661367-4B1B1DC3-1763-434A-82F1-B3849B104BA6Q33680814-0D96FC2E-AEBC-4B34-8962-99B540D2BFCCQ33758772-911165AD-5C7A-4B26-8824-7CAF1E988055Q34100598-65E556D9-B045-4ACF-B8D0-9337E99DFABFQ34351558-FD855644-C6C1-4804-ADB6-FDD1FBC8EB85Q34505582-1C37E300-EDCC-49C1-9C13-BC34EE5E42A1Q34930227-C2F8D6C0-13DB-464B-A41C-E765176744EAQ35071660-73D7434A-A4DC-4639-8756-12A44FA9BAA9Q35097956-1BDEB9E3-2C0E-4A0F-83B5-119B6358D883Q35098515-73CB62F1-7713-4141-9B03-4A05C3276CDAQ35188272-1B8541FE-3F8F-4E84-86FD-70270E3E79DDQ35566061-A156DE93-0CB6-42A1-8CD4-983CB1586C06Q35681680-C486DE6A-CDAA-45F5-9926-3D2549802AA7Q35688413-948B66F1-D05F-4368-8FD0-E80859E4B624Q35756422-4E141F24-EFAC-4F1F-ABE1-E4DD9061247DQ35799819-A66C4B0C-C6DD-4FEE-9702-8A6B04910185Q35847935-904B02C0-1F32-468B-9833-69F66DB52E3AQ35851241-4F1014A1-4F59-4742-958E-9EB38BAE8134Q35974693-65006C5C-1E88-4816-93C5-B82E9B3D3066Q35988608-40C917F5-D51D-4A4D-A4EB-77ADAA8D5620Q36105815-93D28498-D29B-44EF-8997-90FC0B2C0ED3Q36158489-0A62A38D-D697-4FB2-A49F-B8AC7872D0ABQ36305057-7FCA64EC-FFEE-452C-A61D-5060783C0D59
P2860
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@ast
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@en
type
label
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@ast
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@en
prefLabel
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@ast
Epidemiology and outcomes of c ...... lliance®) registry, 2004-2008.
@en
P2093
P1476
Epidemiology and outcomes of c ...... Alliance®) registry, 2004-2008
@en
P2093
David Horn
Herwig-Ulf Meier-Kriesche
Michael Pfaller
Nkechi Azie
Shun-Ping Quan
P304
P356
10.1016/J.DIAGMICROBIO.2012.10.003
P577
2012-10-25T00:00:00Z